FcγRIIB expression was found decreased in treatment-naïve CIDP patients and was upregulated after clinically effective IVIg therapy suggesting that FcγRIIB may be a factor predicting patients more likely to respond to IVIg [2]. Here, FCGR2B is linked to chronic inflammatory demyelinating polyradiculoneuropathy.